Ceribell, founded by Stanford University faculty members, is a venture-backed medical device startup focused on revolutionizing neurodiagnostics. The company's core mission is to make the diagnosis of neurological conditions more efficient through innovative technology. Ceribell has developed a groundbreaking electroencephalography (EEG) device that enables rapid and accurate diagnosis of neurological patients, particularly in critical care settings. Their market focus includes hospitals and medical centers that require advanced neurodiagnostic tools to improve patient outcomes.

Notable affiliated individuals include neurologists Harrison Pearl, MD, from Mobile Infirmary Medical Center, and Paul Vespa, MD, from UCLA, who have both endorsed Ceribell's technology. The company has achieved significant milestones, such as being the first critical care monitoring and neurodiagnostic device to achieve specific regulatory approvals. Ceribell's impact is evident in its ability to enhance the efficiency and effectiveness of neurological care, making it a valuable asset in the medical community.